San Diego, California — According to state and local economic development sources Mirati Therapeutics plans to invest $4,331,906.00 to build out 50,371 square feet of new space in San Diego. The company plans to occupy the new space at 3545 Cray Ct in San Diego, on or about October 1, 2020. According to the company website Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati’s approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team.

To learn more about Mirati Therapeutics, visit http://www.mirati.com/

Company Contact:
Charles Baum, President and Chief Executive Officer
https://www.linkedin.com/in/charlesbaum/
858-332-3410

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved